Boryung Signs 7-Year Supply Contract with Yifan for Taxotere in China Worth KRW 380 Billion
First Major Contract Following Acquisition Closure in May
Securing a Long-Term Demand Base in the Largest Market
Boryung has secured a seven-year long-term supply foundation for the global original anticancer drug 'Taxotere' (ingredient name: docetaxel) in the Chinese market.
On September 22, Boryung announced that it has signed a contract with Yifan Pharmaceutical to supply Taxotere to the Chinese market. The contract period is a total of seven years and is valued at 277.14 million US dollars (approximately 383.7 billion won). This is the largest supply contract ever signed by Boryung.
Cheng Xianfeng, founder and chairman of Yifan Pharmaceuticals (fifth from left), Kim Jungkyun, CEO of Boryung (sixth from left), and other officials are taking a commemorative photo at the contract signing ceremony held on the 21st at Yifan Pharmaceuticals International Innovation Center in Shanghai, China. Boryung
View original imageThis contract is significant in that, following Boryung's acquisition of the global business rights for Taxotere from Sanofi, the company has secured a long-term demand base in China, the country with the highest sales proportion among the acquired territories.
Boryung plans to stably supply products through its existing production system, while sequentially transferring Taxotere production to its Yesan Campus through technology transfer and country-specific regulatory approval procedures. After the production transfer, the company aims to combine its experience in managing global original brands with the cytotoxic anticancer drug manufacturing capabilities of the Yesan Campus, thereby enhancing both supply stability and business profitability. Previously, Boryung also acquired the domestic business for original cytotoxic anticancer drugs such as Gemzar and Alimta from Eli Lilly and successfully switched to in-house manufacturing.
Boryung plans to apply its global contract development and manufacturing organization (CDMO) experience to the global business operation and production transfer of Taxotere. In addition, the company plans to expand its business model through ▲further acquisitions of global original brands, ▲increased exports of its own products, and ▲CDMO orders from around the world.
The company intends to establish the Yesan Campus as a global essential medicines manufacturing hub, and in the mid- to long-term, will pursue the internalization of active pharmaceutical ingredients (APIs) and improvements in formulations. Through this, Boryung aims to build an integrated business structure that encompasses brand management, regulatory approvals, quality, production, and supply.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kim Sungjin, Executive Vice President and Chief Strategy Officer (CSO) of Boryung, stated, "This contract is meaningful not only because we possess a global brand like Taxotere, but also because Boryung is directly operating the business and securing a long-term supply and demand foundation in key markets." He further added, "We will continue to grow as an 'Essential Pharma Company' responsible for the entire life cycle of high-barrier essential medicines."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.